Biologics Market Size, Trends, Analysis, and Outlook By Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, Others), By Application (Cancer, Infectious Diseases, Autoimmune Diseases, Oth

Biologics Market Size, Trends, Analysis, and Outlook By Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, Others), By Application (Cancer, Infectious Diseases, Autoimmune Diseases, Others), by Region, Country, Segment, and Companies, 2024-2030

The global Biologics market size is poised to register 12.19% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Biologics market across By Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, Others), By Application (Cancer, Infectious Diseases, Autoimmune Diseases, Others).

The Biologics Market is witnessing significant growth and therapeutic innovation in 2024 and beyond, driven by the increasing adoption of biopharmaceuticals, monoclonal antibodies, and cell-based therapies for the treatment of cancer, autoimmune diseases, and chronic inflammatory conditions, as well as the emergence of novel biologic modalities targeting previously undruggable disease pathways and molecular targets. Biologics, also known as biological drugs or biopharmaceuticals, are large molecules derived from living organisms, such as proteins, antibodies, nucleic acids, and cellular therapies, engineered to modulate specific molecular pathways, regulate immune responses, and restore physiological homeostasis in patients with complex diseases. Key trends include the development of next-generation biologic therapies, gene editing technologies, and advanced manufacturing processes to improve biologic drug potency, stability, and delivery, as well as to enhance patient accessibility and affordability through biosimilar and biobetter development programs. Additionally, there is a growing emphasis on precision medicine approaches, biomarker-driven drug development, and patient-centered care models to optimize biologic therapy selection, dosing regimens, and treatment outcomes while minimizing adverse effects and treatment-related costs. Moreover, collaborative partnerships between biopharmaceutical companies, academic research institutions, and healthcare providers are essential for advancing biologics research, conducting clinical trials, and implementing evidence-based treatment guidelines, fostering innovation and improving patient access to safe, effective, and personalized biologic therapies for a wide range of medical conditions and unmet clinical needs.

Biologics Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Biologics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Biologics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Biologics industry.

Key market trends defining the global Biologics demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Biologics Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Biologics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Biologics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Biologics industry

Leading Biologics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Biologics companies.

Biologics Market Study- Strategic Analysis Review

The Biologics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

• Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
• Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
• Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
• Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Biologics Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Biologics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Biologics Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Biologics Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Biologics market segments. Similarly, Strong end-user demand is encouraging Canadian Biologics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Biologics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Biologics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Biologics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Biologics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Biologics Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Biologics in Asia Pacific. In particular, China, India, and South East Asian Biologics markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Biologics Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Biologics Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Biologics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Biologics.

Biologics Market Company Profiles

The global Biologics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Celltrion Healthcare Co. Ltd, Eli Lilly and Company, F. Hoffmann La-Roche Ltd, Johnson & Johnson Services Inc, Novo Nordisk A/S, Samsung Biologics, Sanofi

Recent Biologics Market Developments

The global Biologics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Biologics Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

• Pricing Analysis
• Value Chain Analysis
• SWOT Profile
• Market Dynamics- Trends, Drivers, Challenges
• Porter’s Five Forces Analysis
• Macroeconomic Impact Analysis
• Case Scenarios- Low, Base, High

Market Segmentation:

By Product

Monoclonal Antibodies

Vaccines

Recombinant Hormones/Proteins

Cellular-based Biologics

Gene-based Biologics

Others

By Application

Cancer

Infectious Diseases

Autoimmune Diseases

Others

Geographical Segmentation:

• North America (3 markets)
• Europe (6 markets)
• Asia Pacific (6 markets)
• Latin America (3 markets)
• Middle East Africa (5 markets)

Companies

AbbVie Inc

Amgen Inc

Bristol-Myers Squibb Company

Celltrion Healthcare Co. Ltd

Eli Lilly and Company

F. Hoffmann La-Roche Ltd

Johnson & Johnson Services Inc

Novo Nordisk A/S

Samsung Biologics

Sanofi

Formats Available: Excel, PDF, and PPT